Clinical Trial Update: Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 Pediatric MATCH trial evaluating Ulixertinib for MAPK-pathway-mutant tumors in children, including advanced solid tumors, Non-Hodgkin lymphoma, and hist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Ewing Sarcoma
• Glioma
• Histiocytic and Dendritic Cell Neoplasm
• Langerhans Cell Histiocytosis
• Neuroblastoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Ulixertinib (ulixertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-05-16